Holen Sie sich die Stockscreener-App
2.265
1.80%
0.045
Schlusskurs vom Vortag:
$2.22
Offen:
$2.22
24-Stunden-Volumen:
443.85K
Relative Volume:
0.46
Marktkapitalisierung:
$264.60M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-26.33M
KGV:
-8.0205
EPS:
-0.2824
Netto-Cashflow:
$-17.65M
1W Leistung:
+4.15%
1M Leistung:
+59.15%
6M Leistung:
+130.75%
1J Leistung:
+119.42%
1-Tages-Spanne:
$2.21
$2.34
1-Wochen-Bereich:
$2.085
$2.34
52-Wochen-Spanne:
$0.88
$2.34
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
2.265 | 259.35M | 0 | -26.33M | -17.65M | -0.2824 |
TAK
Takeda Pharmaceutical Co Adr
|
18.30 | 58.50B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.89 | 42.84B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.165 | 40.68B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.48 | 30.40B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
496.47 | 21.36B | 3.17B | 1.29B | 1.01B | 27.09 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-26 | Eingeleitet | ROTH MKM | Buy |
| 2024-04-22 | Eingeleitet | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Aktie (CRDL) Neueste Nachrichten
Heart-drug developer Cardiol Therapeutics (CRDL) heads to a major New York investor conference - Stock Titan
Cardiol Therapeutics will join a heart-disease drug chat in New York Sept. 14 - Stock Titan
Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
Cardiol Therapeutics Inc (CRDL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cardiol Therapeutics Inc. (TSX:CRDL) Climbs 10.18% as Phase III Catalyst and CardiolRx Momentum Strengthen Investor Optimism - kalkine.ca
Cardiol Therapeutics (TSX:CRDL) Falls 5.92% as Clinical Trial Uncertainty and Biotech Sector Volatility Pressure Investor Sentiment - kalkine.ca
Cardiol Therapeutics Inc Class A (CRDL) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Cardiol Therapeutics Stock Falls 3.37%: Is TSX:CRDL Facing Biotech Volatility as Clinical and Funding Risks Persist? - kalkine.ca
Cardiol Therapeutics Inc Class A (CRDL) Peer Comparison – Compare with Others - Value Research
Cardiol Therapeutics Inc. (TSX:CRDL) Gains Momentum as Clinical Pipeline Progress and Heart Disease Therapies Drive Investor Optimism - kalkine.ca
B.Riley initiates Cardiol Therapeutics stock with buy rating on pericarditis drug potential - Investing.com Canada
Cardiol Therapeutics (TSX:CRDL) Rallies 7% as Analyst Upgrades Build on Trial Progress - kalkine.ca
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Cardiol (CRDL) Earnings Snapshot: EPS Lands Above Forecast in the Latest Reading; Share Move: The Stock Loses 1.33% at the CloseMargin Expansion Trends - vinanet.vn
Cardiol (CRDL) Close: Ends Lower by 1.33% at $1.86 in Latest Trading; Technical View: the Supplied Trading Band Runs From $1.77 to $1.95 in the Current UpdateIPO Entry Watch - vinanet.vn
Cardiol Therapeutics Stock Falls 3.33% as Investors Weigh Phase III MAVERIC Promise Against Clinical-Trial and Biotech Execution Risk - kalkine.ca
Cardiol Therapeutics Drops as Biotech Risk Appetite Fades — Could the Next Clinical Update Change Everything? - kalkine.ca
Cardiol Therapeutics Stock Under Pressure as Clinical Execution Risk Tests Investor Confidence - kalkine.ca
Cardiol Therapeutics Inc (CRDL) Stock Price, Trades & News - GuruFocus
Cardiol (CRDL) Quarterly Results: The Bottom-Line Figure Beats Its Comparison in the Latest Session; Price Move: The Stock Ends Down 2.04% in the Current UpdateCFO Commentary Report - vinanet.vn
Cardiol Therapeutics Stock Surges 4.82% as Phase III Progress and CardiolRx Pipeline Support Investor Optimism - kalkine.ca
Why Cardiol Therapeutics Inc Class A stock went up yesterday - Wealth Awesome
Cardiol (CRDL) Financial Results: EPS Exceeds Its Estimate in the Latest Reading; Market Move: The Stock Gains 5.28% on the DayEarnings Manipulation Risk - vinanet.vn
Cardiol Therapeutics Stock: A Pivotal Pericarditis Readout Draws Nearer - kalkine.ca
What's Going On With Cardiol Therapeutics Inc Class A Stock Tuesday? - Wealth Awesome
symbol__ Stock Quote Price and Forecast - CNN
CRDL Maintains Buy Rating by Canaccord Genuity -- Price Target R - GuruFocus
CRDL Q1 2026 Earnings: Narrower-Than-Expected Loss Underscores Pipeline Cost DisciplineShare Dilution Risk - vinanet.vn
Why Cardiol Therapeutics Inc Class A stock is gaining today - Wealth Awesome
Cardiol Therapeutics (CRDL) Advances 5.26% as Shares Test Key Resistance Near $1.89IPO Entry Watch - vinanet.vn
Canaccord Genuity Group Issues Positive Forecast for Cardiol Therapeutics (NASDAQ:CRDL) Stock Price - MarketBeat
CCORF Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Could Cardiol Therapeutics Stock Be Entering a Major Catalyst Phase as MAVERIC Enrollment Nears Completion? - kalkine.ca
Q3 EPS Estimate for Cardiol Therapeutics Raised by Analyst - MarketBeat
Wall Street Zen Upgrades Cardiol Therapeutics (NASDAQ:CRDL) to Hold - MarketBeat
MMCAP and MM Asset Management (CRDL) reveal 21.3M-share Cardiol Therapeutics stake - Stock Titan
Why Cardiol Therapeutics Inc Class A stock is sliding today - Wealth Awesome
Cardiol Therapeutics Inc Class A CRDL Earnings Beat Estimates by 50.0% - Wealth Awesome
Cardiol Therapeutics Inc. Stock Surges 5.66% as Trading Activity Spikes and Market Attention Builds - kalkine.ca
Cardiol Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cardiol Therapeutics Reports Second-Quarter 2026 Interim Results - TipRanks
Cardiol Therapeutics (NASDAQ:CRDL) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat
Cardiol Therapeutics (CRDL) posts Q2 2026 loss but extends cash runway to Q4 2027 - Stock Titan
Cardiol Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
What’s Next For Cardiol Therapeutics (TSX:CRDL) Research? - Kalkine Media
Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial - MarketBeat
Will Cardiol Therapeutics Inc Class A (CRDL) Beat Estimates Again in Its Next Earnings Report? - Wealth Awesome
Cardiol Therapeutics at Canaccord Genuity: Phase III catalyst nears By Investing.com - Investing.com Nigeria
Cardiol Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Cardiol Therapeutics (TSX:CRDL): The Oral Heart Drug Challenging Injectable Biologics Nears Its Big Test - kalkine.ca
Finanzdaten der Cardiol Therapeutics Inc-Aktie (CRDL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.30%
0.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):